Conduit Pharmaceuticals Inc. has announced an amendment to its Form 8-K filing, initially submitted on July 1, 2024, regarding its 2024 annual meeting of stockholders and related deadlines for stockholder proposals. The amendment, filed on July 11, 2024, clarifies the record date for the annual meeting, which is now set for August 12, 2024. The company's Board of Directors has scheduled the 2024 Annual Meeting for October 2, 2024. Due to the absence of an annual meeting in 2023, Conduit Pharmaceuticals is informing shareholders of the July 11, 2024 deadline for the submission of qualified stockholder proposals or director nominations to be included in the proxy statement. All proposals must adhere to the SEC's rules and regulations, including Rule 14a-8 under the Exchange Act, as well as the company's bylaws.

Conduit Pharmaceuticals Inc. has announced an amendment to its Form 8-K filing, initially submitted on July 1, 2024, regarding its 2024 annual meeting of stockholders and related deadlines for stockholder proposals. The amendment, filed on July 11, 2024, clarifies the record date for the annual meeting, which is now set for August 12, 2024. The company's Board of Directors has scheduled the 2024 Annual Meeting for October 2, 2024. Due to the absence of an annual meeting in 2023, Conduit Pharmaceuticals is informing shareholders of the July 11, 2024 deadline for the submission of qualified stockholder proposals or director nominations to be included in the proxy statement. All proposals must adhere to the SEC's rules and regulations, including Rule 14a-8 under the Exchange Act, as well as the company's bylaws.